Stamos Capital Partners L.P. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 69.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,730 shares of the medical research company's stock after purchasing an additional 2,760 shares during the quarter. Stamos Capital Partners L.P.'s holdings in Amgen were worth $1,754,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Amgen by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock valued at $13,741,409,000 after purchasing an additional 339,522 shares during the period. Charles Schwab Investment Management Inc. increased its position in Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares during the period. Geode Capital Management LLC raised its holdings in Amgen by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after purchasing an additional 352,143 shares during the last quarter. Norges Bank acquired a new position in shares of Amgen in the 4th quarter worth approximately $1,541,991,000. Finally, Invesco Ltd. boosted its stake in shares of Amgen by 7.5% in the 4th quarter. Invesco Ltd. now owns 3,887,248 shares of the medical research company's stock valued at $1,013,172,000 after purchasing an additional 270,135 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Stock Performance
AMGN traded down $5.35 during trading on Friday, hitting $277.29. 4,371,822 shares of the company traded hands, compared to its average volume of 2,793,267. The firm has a market cap of $149.09 billion, a P/E ratio of 36.73, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock's fifty day moving average is $303.43 and its 200 day moving average is $294.51.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen's dividend payout ratio is presently 126.09%.
Insider Transactions at Amgen
In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 over the last quarter. Corporate insiders own 0.69% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. Truist Financial lowered their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a research note on Wednesday, January 8th. Johnson Rice set a $294.00 price objective on Amgen in a research report on Wednesday, March 5th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Thursday. UBS Group lifted their target price on Amgen from $315.00 to $319.00 and gave the stock a "neutral" rating in a report on Monday. Finally, Morgan Stanley boosted their price target on Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen currently has an average rating of "Moderate Buy" and a consensus price target of $314.91.
Check Out Our Latest Stock Report on Amgen
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
